Clinical trials: Membranous
Primary Membranous Nephropathy
Phase II Randomized, Open-label, Multicenter Clinical Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of SHR-2173 Injection in Patients With Primary Membranous Nephropathy
To investigate the safety, efficacy, pharmacokinetics, and pharmacodynamics of SHR-2173 injection in patients with primary membranous nephropathy
- Trial name
- NCT07289763
- Testing
- SHR-2173 injection
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Primary Membranous Nephropathy
OBINOTUZUMAB Versus Cyclophosphamide + Glucocorticoids in Primary Membranous Nephropathy(Blossom Study)
This is a randomized, parallel group, active-controlled, open-label, Phase III study comparing the efficacy and safety of obinutuzumab versus cyclophosphamide combined with glucocorticoids in patients with primary membranous…
- Trial name
- NCT06781944
- Testing
- Obinutuzumab, CTX combined with Glucocorticoids
- Where
- China
- Volunteers
- 144 people
- Sponsor
- Huashan Hospital
Membranous Nephropathy - PLA2R Induced
Obinutuzumab Induced Decreases of PLA2R Antibodies in Membranous Nephropathy: a Pilot Study
Objective: To assess the disappearance rate (half-life) of anti-PLA2R antibodies in high-risk primary membranous nephropathy (pMN) patients treated with obinutuzumab (OBI), and to evaluate immunological and clinical remission…
- Trial name
- NCT07163611
- Testing
- Obinutuzumab administration
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- Radboud University Medical Center
Refractory Membranous Nephropathy
Safety and Efficacy of CD19 Chimeric Antigen Receptor T-Cell (CAR-T) in the Treatment of Refractory Membranous Nephropathy
This study is a single-center, prospective, exploratory Phase I clinical trial initiated by the team led by Associate Professor He Lijie from the Department of Nephrology, Xijing Hospital.
- Trial name
- NCT07266181
- Testing
- All patients will receive CD19 CAR-T cell therapy on the basis of standard symptomatic and supportive treatment.
- Where
- China
- Volunteers
- 5 people
- Sponsor
- The First Affiliated Hospital of Air Force Medicial University
Fluid Overload, Glomerulosclerosis, Focal Segmental
Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome.
Researchers from the University of Michigan and Northwestern University are studying people's experiences with swelling caused by Nephrotic Syndrome.
- Conditions
- Fluid Overload, Glomerulosclerosis, Focal Segmental, Edema, Membranous Nephropathy
- Trial name
- Prepare-NS (NCT05505500)
- Testing
- Interview
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- University of Michigan
Kidney Diseases
Global Kidney Patient Trials Network
This is a prospective international multi-centre, observational cohort study of incident and prevalent patients diagnosed with a kidney disease
- Trial name
- GKPTN (NCT04389827)
- Where
- Australia
- Volunteers
- 5,999 people
- Sponsor
- The George Institute
Mid-membranous Vocal Fold Lesion
Laryngeal and Vocal Tract Strategies to Reduce Vocal Fold Contact Pressure
Phonotraumatic vocal hyperfunction is one of the most frequently occurring conditions to affect the voice. This voice disorder often involves vocal fold injury due to repeated, excessive contact pressure between the vocal folds…
- Trial name
- NCT06165536
- Testing
- Resonant voice therapy
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of California, Los Angeles
Idiopathic Membranous Nephropathy
Rituximab Combined With Cyclosporine Versus Rituximab Alone in the Treatment of iMN
The primary objective of this study is to determine whether or not cyclosporine (CsA) combined with RTX is more effective than RTX alone in the treatment of idiopathic membranous nephropathy (iMN).
- Trial name
- NCT04743739
- Testing
- Rituximab, cyclosporine
- Where
- 7 sites in China
- Volunteers
- 12 people
- Sponsor
- Peking Union Medical College Hospital
Idiopathic Membranous Nephropathy
Different Immunosuppressive Treatment in iMN
The primary objective of this study is to compare the 24 month remission of different immunosuppressive therapies in the treatment of idiopathic membranous nephropathy (iMN)
- Trial name
- NCT04745728
- Testing
- Prednisone, Cyclophosphamide, Rituximab
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Peking Union Medical College Hospital
Primary Membranous Nephropathy
REmission in Membranous Nephropathy International Trial (REMIT)
REMIT is an investigator-initiated, international, multi-centre, prospective, randomised, open-label, parallel-group trial. A total of 224 adult participants with Primary Membranous Nephropathy (PMN) will be recruited from renal…
- Trial name
- REMIT (NCT06120673)
- Testing
- Obinutuzumab, Oral prednisolone and cyclophosphamide
- Where
- 13 sites in Australia
- Sponsor
- The University of Queensland
Primary Membranous Nephropathy
A Phase II Study of Zuberitamab Injection in Patients With Primary Membranous Nephropathy
This study is a multicenter, randomized, open label, cyclosporine controlled Phase II trial aimed at evaluating the efficacy, safety, pharmacokinetics, and immunogenicity of Zuberitamab in patients with primary membranous…
- Trial name
- NCT06642909
- Testing
- Zuberitamab 600mg, Zuberitamab 1000mg, cyclosporine
- Where
- China
- Volunteers
- 135 people
- Sponsor
- BioRay Pharmaceutical Co., Ltd.
Membranous Nephropathy, Lupus Nephritis (LN)
A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection Versus Placebo in Patients With Active Glomerulonephritis
The primary objectives of this clinical trial is to evaluate the safety and tolerability of HLX79 in combination with HLX01 versus placebo in combination with HLX01 in the treatment of glomerulonephritis.
- Trial name
- NCT07038382
- Where
- 17 sites in China
- Volunteers
- 24 people
- Sponsor
- Shanghai Henlius Biotech
Primary Membranous Nephropathy
A Phase Ib/ Ⅱ Clinical Study of MIL62 in Primary Membranous Nephropathy
This study was divided into two stages. In the first stage (Phase Ib), 30 subjects were randomly divided into MIL62 600mg, MIL62 1000mg and cyclosporine groups at a ratio of 1:1:1, with 10 subjects in each group.
- Trial name
- NCT05398653
- Testing
- MIL62, Cyclosporine
- Where
- China
- Volunteers
- 94 people
- Sponsor
- Beijing Mabworks Biotech Co., Ltd.
Primary Membranous Nephropathy
Study of YK012 in Primary Membranous Nephropathy
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and preliminary efficacy of YK012 in participants with primary membranous nephropathy (PMN).
- Trial name
- NCT06982729
- Testing
- YK012
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Excyte Biopharma Ltd
Glomerulonephritis, Membranous
Mycophenolate Mofetil in Patients With Progressive Idiopathic Membranous Nephropathy
Cyclosporin decreases proteinuria and improve renal function in patients with idiopathic membranous nephropathy, but has a risk of side effects such as nephrotoxicity.
- Trial name
- MMFPRIMER (NCT01282073)
- Testing
- Mycophenolate mofetil, low dose steroid, Cyclosporin, low dose steroid
- Where
- 9 sites in South Korea
- Volunteers
- 43 people
- Sponsor
- Kyungpook National University Hospital
Primary Membranous Nephropathy
A Real World Study About PMN
The investigators designed a randomized, controlled, multicenter clinical study to compare the efficacy and safety of rituximab combined with hormones versus rituximab monotherapy in the treatment of primary membranous…
- Trial name
- PMNTRWS (NCT06893328)
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Wei Chen
Primary Membranous Nephropathy
A Phase Ⅲ Clinical Study of MIL62 in Primary Membranous Nephropathy
This study will evaluate the efficacy, safety, pharmacokinetics(PK) ,pharmacodynamics（PD）and anti-drug antibodies（ADA） of MIL62 compared with cyclosporine in participants with primary membranous nephropathy (pMN).
- Trial name
- NCT05862233
- Testing
- MIL62, Cyclosporine
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Beijing Mabworks Biotech Co., Ltd.
Idiopathic Membranous Nephropathy
Personalized Medicine for Membranous Nephropathy
Randomized, open label, multicentre (20 sites), prospective trial comparing the efficacy of two therapeutic strategies to obtain clinical remission 1 year after diagnosis of Idiopathic Membranous Nephropathy with nephrotic…
- Trial name
- PMMN (NCT03804359)
- Testing
- Rituximab
- Where
- 19 sites in France
- Volunteers
- 68 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Primary Membranous Nephropathy
A Study to Learn More About the Effects and Safety of JMT601 in Adults With Primary Membranous Nephropathy
This study is a multicenter, randomized, controlled, open-label, Phase Ⅱ clinical study to evaluate the efficacy, safety, Pharmacokinetics characteristics, Pharmacodynamics effects, and immunogenicity of JMT601 in participants…
- Trial name
- NCT07029139
- Testing
- JMT601 Injection, Rituximab, Cyclosporin Capsules
- Volunteers
- 156 people
- Sponsor
- Shanghai JMT-Bio Inc.
Nephrotic Syndrome, Thromboembolic Disease
Causes and Prevention of Thromboembolic Disease in Nephrotic Syndrome
The study aims to describe the biochemical coagulation profile and investigate the effect of Low molecular weight heparin and Apixaban on this profile in patients with nephrotic syndrome.
- Trial name
- CAPTAIN (NCT04850378)
- Testing
- Dalteparin, Apixaban
- Where
- Denmark
- Volunteers
- 57 people
- Sponsor
- University of Aarhus